Determining the Utility of the Guillain-Barré Syndrome Classification Criteria
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Several variants of Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS) exist, but their frequencies vary in different populations and do not always meet the inclusion criteria of the existing diagnostic criteria. However, the GBS classification criteria by Wakerley and colleagues recognize and define the clinical characteristics of each variant. We applied these criteria to a GBS and MFS cohort with the aim of determining their utility. Methods Consecutive GBS and MFS patients presenting to our center between 2010 and 2020 were analyzed. The clinical characteristics, electrophysiological data, and antiganglioside antibody profiles of the patients were utilized in determining the clinical classification. Results This study classified 132 patients with GBS and its related disorders according to the new classification criteria as follows: 64 (48.5%) as classic GBS, 2 (1.5%) as pharyngeal-cervical- brachial (PCB) variant, 7 (5.3%) as paraparetic GBS, 29 (22%) as classic MFS, 3 (2.3%) as acute ophthalmoparesis, 2 (1.5%) as acute ataxic neuropathy, 2 (1.5%) as Bickerstaff brainstem encephalitis (BBE), 17 (12.9%) as GBS/MFS overlap, 4 (3%) as GBS/BBE overlap, 1 (0.8%) as MFS/PCB overlap, and 1 (0.8%) as polyneuritis cranialis. The electrodiagnosis was demyelinating in 55% of classic GBS patients but unclassified in 79% of classic MFS patients. Anti-GM1, anti-GD1a, anti-GalNAc-GD1a, and anti-GD1b IgG ganglioside antibodies were more commonly detected in the axonal GBS subtype, whereas the anti-GQ1b and anti-GT1a IgG ganglioside antibodies were more common in classic MFS and its subtypes. Conclusions Most of the patients in the present cohort met the criteria of either classic GBS or MFS, but variants were seen in one-third of patients. These findings support the need to recognize variants of both syndromes in order to achieve a more-complete case ascertainment in GBS.
Abstract
Background and Purpose Several variants of Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS) exist, but their frequencies vary in different populations and do not always meet the inclusion criteria of the existing diagnostic criteria. However, the GBS classification criteria by Wakerley and colleagues recognize and define the clinical characteristics of each variant. We applied these criteria to a GBS and MFS cohort with the aim of determining their utility. Methods Consecutive GBS and MFS patients presenting to our center between 2010 and 2020 were analyzed. The clinical characteristics, electrophysiological data, and antiganglioside antibody profiles of the patients were utilized in determining the clinical classification. Results This study classified 132 patients with GBS and its related disorders according to the new classification criteria as follows: 64 (48.5%) as classic GBS, 2 (1.5%) as pharyngeal-cervical- brachial (PCB) variant, 7 (5.3%) as paraparetic GBS, 29 (22%) as classic MFS, 3 (2.3%) as acute ophthalmoparesis, 2 (1.5%) as acute ataxic neuropathy, 2 (1.5%) as Bickerstaff brainstem encephalitis (BBE), 17 (12.9%) as GBS/MFS overlap, 4 (3%) as GBS/BBE overlap, 1 (0.8%) as MFS/PCB overlap, and 1 (0.8%) as polyneuritis cranialis. The electrodiagnosis was demyelinating in 55% of classic GBS patients but unclassified in 79% of classic MFS patients. Anti-GM1, anti-GD1a, anti-GalNAc-GD1a, and anti-GD1b IgG ganglioside antibodies were more commonly detected in the axonal GBS subtype, whereas the anti-GQ1b and anti-GT1a IgG ganglioside antibodies were more common in classic MFS and its subtypes. Conclusions Most of the patients in the present cohort met the criteria of either classic GBS or MFS, but variants were seen in one-third of patients. These findings support the need to recognize variants of both syndromes in order to achieve a more-complete case ascertainment in GBS.
참고문헌 (50)
- Willison HJ, "Guillain-Barré syndrome", Lancet, 388, pp.717~727 (2016)
- Ropper AH, "Unusual clinical variants and signs in Guillain-Barré syndrome", Arch Neurol, 43, pp.1150~1152 (1986)
- Ropper AH, "Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness", Arch Neurol, 51, pp.671~675 (1994)
- Shahrizaila N, "Bickerstaff brainstem encephalitis and Fisher syndrome : anti-GQ1b antibody syndrome", J Neurol Neurosurg Psychiatry, 84, pp.576~583 (2013)
- Asbury AK, "Assessment of current diagnostic criteria for Guillain-Barré syndrome", Ann Neurol, 27(Suppl), pp.S21~S24 (1990)
- Sejvar JJ, "Guillain-Barré syndrome and Fisher syndrome : case definitions and guidelines for collection, analysis, and presentation of immunization safety data", Vaccine, 29, pp.599~612 (2011)
- Tan CY, "Diagnosis of GuillainBarré syndrome and validation of the Brighton criteria in Malaysia", J Peripher Nerv Syst, 25, pp.256~264 (2020)
- Wakerley BR, "GuillainBarré and Miller Fisher syndromes--new diagnostic classification", Nat Rev Neurol, 10, pp.537~544 (2014)
- Wakerley BR, "Polyneuritis cranialis--subtype of Guillain-Barré syndrome?", Nat Rev Neurol, 11, pp.664~ (2015)
- Wakerley BR, "Clinical classification of 103 Japanese patients with Guillain-Barrésyndrome", J Neurol Sci, 369, pp.43~47 (2016)
- Grapperon AM, "Guillain-Barré syndrome subtypes: a clinical electrophysiological study of 100 patients", Rev Neurol(Paris), 175, pp.73~80 (2019)
- Hiew FL, "Guillain-Barrésyndrome, variants & forms fruste : reclassification with new criteria", Clin Neurol Neurosurg, 158, pp.114~118 (2017)
- van der Meché FG, "Diagnostic and classification criteria for the Guillain-Barrésyndrome", Eur Neurol, 45, pp.133~139 (2001)
- Kleyweg RP, "Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome", Muscle Nerve, 14, pp.1103~1109 (1991)
- Plasma Exchange, "Sandoglobulin Guillain-Barré Syndrome Trial Group", Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome, 1997, pp.349, 225~230
- Shahrizaila N, "Serial nerve conduction studies provide insight into the pathophysiology of Guillain-Barré and Fisher syndromes", J Neurol Sci, 309, pp.26~30 (2011)
- Uncini A, "Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes : criteria sets and sparse linear discriminant analysis", Clin Neurophysiol, 128, pp.1176~1183 (2017)
- Tan CY, "A model to predict the probability of acute inflammatory demyelinating polyneuropathy", Clin Neurophysiol, 131, pp.63~69 (2020)
- Yuki N, "Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α", J Neuroimmunol, 74, pp.30~34 (1997)
- Lyu RK, "Guillain-Barré syndrome in Taiwan : a clinical study of 167 patients", J Neurol Neurosurg Psychiatry, 63, pp.494~500 (1997)
- Mori M, "Clinical features and prognosis of Miller Fisher syndrome", Neurology, 56, pp.1104~1106 (2001)
- Beghi E, "The Guillain-Barrèsyndrome(GBS). Implementation of a register of the disease on a nationwide basis", Ital J Neurol Sci, 17, pp.355~361 (1996)
- Carpo M, "Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies", J Neurol Sci, 168, pp.78~84 (1999)
- Fokke C, "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria", Brain, 137(Pt 1), pp.33~43 (2014)
- Lin JJ, "Clinical variants of Guillain-Barré syndrome in children", Pediatr Neurol, 47, pp.91~96 (2012)
- Shahrizaila N, "Sensory nerves are frequently involved in the spectrum of Fisher syndrome", Muscle Nerve, 49, pp.558~563 (2014)
- Zhang G, "Subtypes and prognosis of Guillain-Barré syndrome in Southwest China", PLoS One, 10, pp.e0133520~ (2015)
- Kim JK, "Acute bulbar palsy as a variant of Guillain-Barré syndrome", Neurology, 86, pp.742~747 (2016)
- Arai M, "Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without anti-GT1a IgG antibody", Muscle Nerve, 28, pp.246~250 (2003)
- Capasso M, "Reversible conduction failure in pharyngeal-cervical-brachial variant of GuillainBarré syndrome", Muscle Nerve, 42, pp.608~612 (2010)
- Nagashima T, "Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome", Arch Neurol, 64, pp.1519~1523 (2007)
- Wakerley BR, "Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome", J Neurol Neurosurg Psychiatry, 85, pp.339~344 (2014)
- Nagashima T, "Paraparetic Guillain-Barré syndrome : extending the axonal spectrum", Neurol Clin Neurosci, 1, pp.224~226 (2013)
- Kimachi T, "Paraparetic Guillain-Barré syndrome : nondemyelinating reversible conduction failure restricted to the lower limbs", Muscle Nerve, 55, pp.281~285 (2017)
- Tan CY, "Association of dengue infection and Guillain-Barré syndrome in Malaysia", J Neurol Neurosurg Psychiatry, 90, pp.1298~1300 (2019)
- Sekiguchi Y, "Patterns of sensory nerve conduction abnormalities in Fisher syndrome : more predominant involvement of group Ia afferents than skin afferents", Clin Neurophysiol, 124, pp.1465~1469 (2013)
- Ito M, "Bickerstaff’s brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases", J Neurol, 255, pp.674~682 (2008)
- Ho TW, "Guillain-Barré syndrome in northern China relationship to Campylobacter jejuni infection and anti-glycolipid antibodies", Brain, 118(Pt 3), pp.597~605 (1995)
- Ogawara K, "Axonal Guillain-Barré syndrome : relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan", Ann Neurol, 48, pp.624~631 (2000)
- Ogawara K, "AntiGM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection", J Neurol Sci, 210, pp.41~45 (2003)
- Susuki K, "Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers", J Neurosci, 27, pp.3956~3967 (2007)
- Susuki K, "Dysfunction of nodes of Ranvier : a mechanism for anti-ganglioside antibody-mediated neuropathies", Exp Neurol, 233, pp.534~542 (2012)
- Odaka M, "Bickerstaff’s brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome", Brain, 126(Pt 10), pp.2279~2290 (2003)
- Chiba A, "Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome : clinical and immunohistochemical studies", Neurology, 43, pp.1911~1917 (1993)
- Koga M, "Anti-GT1a IgG in Guillain-Barré syndrome", J Neurol Neurosurg Psychiatry, 72, pp.767~771 (2002)
- van den Berg B, "Paraparetic Guillain-Barré syndrome", Neurology, 82, pp.1984~1989 (2014)
- Ito M, "Ataxic GuillainBarré syndrome and acute sensory ataxic neuropathy form a continuous spectrum", J Neurol Neurosurg Psychiatry, 82, pp.294~299 (2011)
- Kusunoki S, "Binding of antibodies against GM1 and GD1b in human peripheral nerve", Muscle Nerve, 20, pp.840~845 (1997)
- Bourque PR, "Cerebrospinal fluid total protein in Guillain-Barré syndrome variants : correlations with clinical category, severity, and electrophysiology", J Neurol, 267, pp.746~751 (2020)
- Wong AH, "Cytoalbuminologic dissociation in Asian patients with Guillain-Barréand Miller Fisher syndromes", J Peripher Nerv Syst, 20, pp.47~51 (2015)